Evidence map›Paper›PMID 33164933›Full record

ArticleJournal of Alzheimer's disease : JAD2020

Revised Framingham Stroke Risk Profile: Association with Cognitive Status and MRI-Derived Volumetric Measures.

Isabelle Pelcher, Christian Puzo, Yorghos Tripodis, Hugo J Aparicio, Eric G Steinberg, Alyssa Phelps, Brett Martin, Joseph N Palmisano, Elizabeth Vassey, Cutter Lindbergh and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Isabelle PelcherBoston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, MA, USA.
Christian PuzoBoston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, MA, USA.
Yorghos TripodisDepartment of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Hugo J AparicioBoston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, MA, USA.
Eric G SteinbergBoston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, MA, USA.
Alyssa PhelpsBoston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, MA, USA.
Brett MartinBiostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, MA, USA.
Joseph N PalmisanoBiostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, MA, USA.
Elizabeth VasseyBoston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, MA, USA.
Cutter LindberghDepartment of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Ann C McKeeBoston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, MA, USA.
Thor D SteinBoston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, MA, USA.
Ronald J KillianyBoston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, MA, USA.
Rhoda AuBoston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, MA, USA.
Neil W KowallBoston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, MA, USA.
Robert A SternBoston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, MA, USA.
Jesse MezBoston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, MA, USA.
Michael L AloscoBoston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, MA, USA.

Funding

NATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8M
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1M
Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SWEET, ROBERT A · 1985 to 2019
$43.0M
VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHUI, HELENA CHANG · 1985 to 2019
$41.0M
VESICULAR LOCALIZATION AND FUNCTION OF PRESENILIN 1 FRAGMENTP50AG005138 · NIA · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI GROSSMAN, HILLEL · 1985 to 2019
$37.9M
'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI BANDEEN-ROCHE, KAREN J. · 1985 to 2019
$37.6M
Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 1991 to 2020
$37.3M
NCATS NIH HHS UL1 TR001430NIA NIH HHS K23 AG046377NIA NIH HHS P30 AG008017NIA NIH HHS P30 AG008051NIA NIH HHS P30 AG010124NIA NIH HHS P30 AG010129NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG012300NIA NIH HHS P30 AG013846NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG028383NIA NIH HHS P30 AG035982NIA NIH HHS P30 AG049638NIA NIH HHS P30 AG053760NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062428NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062715NIA NIH HHS P50 AG005133NIA NIH HHS P50 AG005136NIA NIH HHS P50 AG005138NIA NIH HHS P50 AG005142NIA NIH HHS P50 AG005146NIA NIH HHS P50 AG005681NIA NIH HHS P50 AG008702NIA NIH HHS P50 AG016573NIA NIH HHS P50 AG023501NIA NIH HHS P50 AG025688NIA NIH HHS P50 AG047266NIA NIH HHS P50 AG047270NIA NIH HHS P50 AG047366NIA NIH HHS R01 AG054076NIA NIH HHS U01 AG016976NIA NIH HHS U24 AG072122NINDS NIH HHS K23 NS102399NINDS NIH HHS L30 NS093634NINDS NIH HHS U01 NS093334
6 · The paper itself

Abstract

backgroundThe Framingham Stroke Risk Profile (FSRP) was created in 1991 to estimate 10-year risk of stroke. It was revised in 2017 (rFSRP) to reflect the modern data on vascular risk factors and stroke risk.

objectiveThis study examined the association between the rFSRP and cognitive and brain aging outcomes among participants from the National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS).

methodsCross-sectional rFSRP was computed at baseline for 19,309 participants (mean age = 72.84, SD = 8.48) from the NACC-UDS [9,697 (50.2%) normal cognition, 4,705 (24.4%) MCI, 4,907 (25.4%) dementia]. Multivariable linear, logistic, or ordinal regressions examined the association between the rFSRP and diagnostic status, neuropsychological test performance, CDR® Sum of Boxes, as well as total brain volume (TBV), hippocampal volume (HCV), and log-transformed white matter hyperintensities (WMH) for an MRI subset (n = 1,196). Models controlled for age, sex, education, racial identity, APOEɛ4 status, and estimated intracranial volume for MRI models.

resultsThe mean rFSRP probability was 10.42% (min = 0.50%, max = 95.71%). Higher rFSRP scores corresponded to greater CDR Sum of Boxes (β= 0.02, p = 0.028) and worse performance on: Trail Making Test A (β= 0.05, p < 0.001) and B (β= 0.057, p < 0.001), and Digit Symbol (β= -0.058, p < 0.001). Higher rFSRP scores were associated with increased odds for a greater volume of log-transformed WMH (OR = 1.02 per quartile, p = 0.015). No associations were observed for diagnosis, episodic memory or language test scores, HCV, or TBV.

conclusionThese results support the rFSRP as a useful metric to facilitate clinical research on the associations between cerebrovascular disease and cognitive and brain aging.

Indexed as

Blood PressureCognitionAgedAged, 80 and overAge FactorsAntihypertensive AgentsAtrial FibrillationBrainCardiovascular DiseasesCognitive DysfunctionDiabetes MellitusFemaleHippocampusHumansMagnetic Resonance ImagingMaleAntihypertensive AgentsAlzheimer’s diseasecardiovascular diseasecerebrovascular diseaseframingham stroke risk profilestroke risk

Identifiers

PMID33164933
PMCPMC7887636

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.